Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 12, Issue 1, 2012, Pages 125-130

  Bennie, Marion ^a,b   Godman, Brian ^c,d,e   Bishop, Iain ^b   Campbell, Stephen ^f  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b INFORMATION SERVICES DIVISION   (United Kingdom)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^e UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

demand side reforms; drug utilization; generics; prescribing efficiency; Scotland

Indexed keywords

ATORVASTATIN; ESOMEPRAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEPRAZOLE; PROTON PUMP INHIBITOR; ROSUVASTATIN; SIMVASTATIN;

COST CONTROL; DOSE CALCULATION; DRUG COST; DRUG EFFICACY; DRUG STABILITY; DRUG UTILIZATION; HUMAN; PRESCRIPTION; REVIEW; UNITED KINGDOM;

DRUGS, GENERIC; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSURANCE, HEALTH, REIMBURSEMENT; INSURANCE, PHARMACEUTICAL SERVICES; OMEPRAZOLE; PHYSICIAN'S PRACTICE PATTERNS; PROTON PUMP INHIBITORS; PYRROLES; SCOTLAND; SIMVASTATIN;

EID: 84856509046     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.11.98     Document Type: Review

References (21)

1. Godman B, Shrank W, Andersen M et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilisation: changes seen and global implications. Expert Rev. Pharmacoeconomics Outcomes Res. 10(6), 707-722 (2010).
2. Godman B, Shrank W, Andersen M et al. Policies to enhance prescribing efficiency in Europe: findings and future implications. Front. Pharmacol. 1(141), 1-16 (2011).
3. Duerden M. Making sense of drug pricing. In: Prescriber Supplement 1-5. John Wiley & Sons Ltd, Chichester, UK (2006).
4. Chaplin S, Duerdin M. When Brands are Best: Brand vs. Generic Prescribing: Prescriber Guide. Wiley Interface Ltd, NJ, USA (2006).
5. McGinn D, Godman B, Lonsdale J et al. Initiatives to enhance the efficiency of statin and proton pump inhibitor prescribing in the UK; impact and implications. Expert Rev. Pharmacoeconomics Outcomes Res. 10(1), 73-85 (2010).
6. Kanavos P. Do generics offer significant savings to the UK national health service? Curr. Med. Res. Opin. 23, 105-116 (2007). (Pubitemid 46191676)
7. Godman B, Shrank W, Wettermark B et al. Use of generics - a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals 3, 2470-2494 (2010).
8. Smith PC, York N. Quality incentives: the case of UK general practioners. Health Affairs 23, 112-118 (2004).
9. Doran T, Fullwood C, Gravelle H et al. Pay-for-performance programs in family practices in the United Kingdom. N. Engl. J. Med. 355, 375-384 (2006). (Pubitemid 44127540)
10. Collins R, Armitage J, Parish S et al. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361, 2005-2016 (2003).
11. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology and the European Association for the Study of Diabetes. Eur. Heart J. 28, 88-136 (2007).
12. Godman B, Haycox A, Schwabe U et al. Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics 26, 91-98 (2008).
13. Norman C, Zarrinkoub R, Hasselström J et al. Potential savings without compromising the quality of care. Int. J. Clin. Pract. 63, 1320-1326 (2009).
14. Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int. J. Clin. Pract. 62, 480-484 (2008). (Pubitemid 351197428)
15. Hjemdahl P, Allhammar A, Heaton C et al. SBU should investigate what is an evidencebased and cost-effective use of statins. Läkartidningen 32, 1992-1994 (2009).
16. Feely J, Bennett K. Epidemiology and economics of statin use. Ir. Med. J. 101, 188-191 (2008).
17. Vončina L, Strizrep T, Godman B et al. Influence of prescribing restrictions compared with other demand side measures to enhance renin-angiotensin prescribing efficiency: implications for other countries. Expert Rev. Pharmacoeconomics Outcomes Res. 11, 469-479 (2011).
18. Gustafsson LL, Wettermark B, Godman B et al. The 'wise list' - a comprehensive concept to select, communicate and achieve adherence to recommendations of essential drugs in ambulatory care in Stockholm. Basic Clin. Pharmacol. Toxicol. 108, 224-233 (2011).
19. Moon J, Flett A, Godman B, Grosso A, Wierzbicki A. Getting better value from the NHS drug budget. BMJ 342, 30-32 (2011).
20. Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp F. Soft regulations in pharmaceutical policymaking - an overview of current approaches and their consequences. Appl. Health Econ. Health Policy 7, 137-147 (2009).
21. Duerden M, Miller J, Godman B et al. Centralised guidance - how NICE and SIGN impact on care in the UK. In:Bausteine Für Ein Neues Gesundheitswesen. Klusen N, Straub C (Eds). Nomos Verlagsgesellschaft, Baden-Baden, Germany, 51-61 (2003).